Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dato-DXd plus platinum versus gemcitabine plus platinum in previously treated locally advanced or metastatic urothelial carcinoma
NL-OMON60869Phase 3Not yet recruiting
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- Dec 2025
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of datopotamab deruxtecan in transitional cell carcinoma (TCC) (4 arms), sponsored by Daiichi Sankyo Co., Ltd. Primary endpoints: Overall response rate, Progression-free survival and 1 more. Planned start Dec 2025; status: not yet recruiting.
02
Drugs
datopotamab deruxtecan
03
Conditions
transitional cell carcinoma (TCC)
Beyond the preview
Go deeper on NL-OMON60869.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60869.